CoChat

The DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.

The Glucagon-Like Peptide-1 Receptor—or Not?

Pyke, Charles, Knudsen, Lotte Bjerre · 2013 · Endocrinology

Abstract

Glucagon-like peptide-1 (GLP-1)-based diabetes therapy is increasingly used in the treatment of type 2 diabetes. Two GLP-1 analogs, liraglutide and exenatide, have been approved for clinical use and act as agonists of the GLP-1 receptor (GLP-1R), a member of the glucagon receptor family of G protein-coupled receptors (GPCRs) (1). Also, the clinical effect of Di-Peptidyl Peptidase-4 (DPP-4) inhibitors is at least partially resulting from an increased level of active GLP-1 (2). The unambiguous identification of GLP-1R-expressing cells in humans and animal species constitutes critically important knowledge for fully understanding the pharmacological effects of GLP-1R agonists, both those associated with the documented clinical benefits as well as any potential undesired effects of treatment. The GLP-1R was cloned in 1992 (3). Preceding that, the receptor was identified in numerous cell types and organs, most obviously the pancreatic β-cell but also in rat lung and brain by studies using either ligand binding or functional assays (4, 5). After the receptor was cloned, RT-PCR and in situ hybridization were used to report tissue distribution, and the receptor was located in the intestine, stomach, kidney, lungs, heart, and brain (6, 7). Later studies have used Western blotting and immunohistochemistry to identify the exact cellular localization of the receptor. Using such techniques, the receptor has been identified in mouse cardiomyocytes and smooth muscle cells in the heart, and in porcine tubular cells in the kidney (8, 9). Human GLP-1R expression has been mapped by in situ ligand binding across a wide range of both normal and tumor tissues (10). In this issue of Endocrinology, Panjwani et al. (11) reports new knowledge about the mechanism of action of GLP-1 analogs in atherosclerosis and hepatic steatosis and challenges some GLP-1R expression data in macrophages and hepatocytes that have previously been published. When Panjwani et al. (11) could not identify GLP-1R mRNA on macrophages or isolated hepatocytes despite previous reports of such localization, they did a careful Western blotting characterization of three commercially available polyclonal antibodies (PAbs) against the GLP-1R that are commonly used for Western blotting. They used mouse wild-type lung tissue that has a very high expression of GLP-1R as a positive control and lung tissue from GLP-1R−/− mice as a negative control. They also employed a very thorough procedure with immunoprecipitation in an attempt to increase the sensitivity of the analysis but found no GLP-1R-specific expression. The authors conclude that multiple commercially available GLP-1R antibodies do not detect authentic GLP-1R protein, even using optimally enhanced methods. This technical difficulty at first glance seems to have little bearing on aspects of GLP-1 biology unrelated to the scope of the article; however, on further consideration, it brings into focus a potentially serious problem with the validity of any GLP-1R expression data generated through the use of antibodies. Adding to the complexity, for some GLP-1R-containing organs, markedly different GLP-1R expression patterns have been reported between human and rodent species (10, 12). Rodent thyroid C-cells express much higher levels of GLP-1R than primates (10, 12), and there may be an important species difference, where the GLP-1R in the rodent thyroid is important for the high bone turnover in those species but less important in humans (13, 14). In the lung, the number of GLP-1R-expressing cells and the receptor density is much lower in humans than in rodent species (10), but the role and importance of lung GLP-1R is relatively unexplored. Three different histological techniques are available for mapping the identity of cells expressing a receptor like the GLP-1R. First, in situ hybridization is the method of choice for detecting mRNA in tissues; however, for a low-abundance target like the GLP-1R, only methods depending on the use of radioactively labeled probes will provide the required sensitivity, and unfortunately, the final autoradiography step severely limits the resolution of the output signal. A similar problem exists for in situ ligand binding (ISLB) with radioactively labeled ligand, although this method has been highly useful for detecting a functional GLP-1R in cell types that can be identified despite the limited resolution (12, 15). The third method, and the one most often employed to map GLP-1R localization by researchers in the field, is immunohistochemistry (IHC) with anti-GLP-1R antibodies. IHC offers the best resolution and allows unambiguous cell identification; however, for GPCRs, it is notoriously difficult, and a high focus on validation of antibodies and protocols is imperative. Further adding to the difficulty of generating reliable GPCR protein expression data, the normal physiological cell density of many GPCRs can be very low. In one issue of the journal Naunyn-Schmiedeberg’s Archives

Overview

Integrity signals

Registry

Crossref · 10.1210/en.2012-2124

Cites

29 of 29 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 29 references

Cited by

See all 171

Metadata

Authors
Pyke, C., & Knudsen, L. B.
Affiliations
Novo Nordisk (Denmark) (DK)
Corresponding author
Knudsen, Lotte Bjerre
Venue
Endocrinology
Published
2013-01-01
Volume
154
Issue
1
Pages
4-8
ISSN
  • 0013-7227 (ISSN-L)
  • 1945-7170
OpenAlex
W2050866589
Cited by
154
References
29
Citations by year
2026: 5 · 2025: 5 · 2024: 4 · 2023: 5 · 2022: 8 · 2021: 10 · 2020: 19 · 2019: 11 · 2018: 6 · 2017: 18 · 2016: 11 · 2015: 19 · 2014: 24 · 2013: 9
FWCI
13.61
Type
journal article
Language
en
Open access
closed
Locations
  • Endocrinology (publishedVersion)
  • PubMed (publishedVersion)
Funders
Novo Nordisk
Topics
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Receptor Mechanisms and Signaling
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Pancreatic function and diabetes
Keywords
GLP-1 receptor, GLP-1 receptor agonists, liraglutide, exenatide, DPP-4 inhibitors, macrophages, hepatocytes, receptor localization, type 2 diabetes, atherosclerosis, hepatic steatosis, G protein-coupled receptors
MeSH terms
Glucagon-Like Peptide-1 Receptor, Animals, Diabetes Mellitus, Type 2, Humans, Hypoglycemic Agents, Receptors, Glucagon, Glucagon-Like Peptide 1

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: The Glucagon-Like Peptide-1 Receptor—or Not? https://app.cochat.ai/papers/10.1210/en.2012-2124
The paper
Pyke, C., & Knudsen, L. B. (2013). The Glucagon-Like Peptide-1 Receptor—or Not? Endocrinology. https://doi.org/10.1210/en.2012-2124

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.